StockNews.AI
PODD
StockNews.AI
221 days

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

1. Insulet will report Q4 2024 financial results on February 20, 2025. 2. A conference call will follow the results announcement at 4:30 p.m. ET. 3. Omnipod platform is designed for simplified insulin delivery for diabetes management.

Earnings
+0.54%Current Return
VS
-1.53%S&P 500
$270.3601/10 06:03 AM EDTEvent Start
$271.8301/13 06:29 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The earnings announcement could have a mild effect like past releases.

How important is it?

The upcoming earnings report is significant but typical in importance.

Why Short Term?

Earnings results tend to impact stock prices mainly in the short run.

Related Companies

PODD
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com. ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. Source: Insulet Corporation

Related News